{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:12:44Z","timestamp":1793301164939,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR131157"],"award-info":[{"award-number":["NIHR131157"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR131175"],"award-info":[{"award-number":["NIHR131175"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR150308"],"award-info":[{"award-number":["NIHR150308"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_U120097115"],"award-info":[{"award-number":["MC_U120097115"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L003988\/1"],"award-info":[{"award-number":["MR\/L003988\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V013734\/1"],"award-info":[{"award-number":["MR\/V013734\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W005557\/1"],"award-info":[{"award-number":["MR\/W005557\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013376","name":"King's College London Institute of Psychiatry Psychology & Neuroscience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["094849\/Z\/10\/Z"],"award-info":[{"award-number":["094849\/Z\/10\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.biopsych.2025.06.011","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:10:16Z","timestamp":1750677016000},"page":"517-526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Why Is Clozapine Uniquely Effective in Treatment-Resistant Schizophrenia? A Review and Proposal"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0829-0519","authenticated-orcid":false,"given":"Robin M.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Egerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A.","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Jauhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Y.H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"MacCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Natesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2025.06.011_bib1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2025.06.011_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: Systematic review and meta-analysis","volume":"220","author":"Siskind","year":"2022","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib4","first-page":"1","volume":"268","year":"2024","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2025.06.011_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/archpsyc.1993.01820140084012","article-title":"Neuropharmacologic basis for clozapine\u2019s unique profile","volume":"50","author":"Tandon","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s13311-017-0552-9","article-title":"Clozapine as a model for antipsychotic development","volume":"14","author":"Nucifora","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biopsych.2025.06.011_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108236","article-title":"Clozapine\u2019s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia","volume":"236","author":"de Bartolomeis","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2025.06.011_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: Paths to antipsychotic resistance and a roadmap for future research. npj","volume":"6","author":"Potkin","year":"2020","journal-title":"Schizophr"},{"key":"10.1016\/j.biopsych.2025.06.011_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41380-018-0042-4","article-title":"Determinants of treatment response in first-episode psychosis: An 18F-DOPA PET study","volume":"24","author":"Jauhar","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib10","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1017\/S0033291719002083","article-title":"Predictors of treatment resistant schizophrenia: A systematic review of prospective observational studies","volume":"51","author":"Smart","year":"2021","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2025.06.011_bib12","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: Clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2025.06.011_bib13","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: Prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2025.06.011_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033291721004128","article-title":"Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: A meta-analysis","volume":"52","author":"Millgate","year":"2022","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2025.06.011_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2215-0366(15)00540-4","article-title":"Brain-imaging studies of treatment-resistant schizophrenia: A systematic review","volume":"3","author":"Mouchlianitis","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/schbul\/sbac175","article-title":"Increased prevalence of rare copy number variants in treatment-resistant psychosis","volume":"49","author":"Farrell","year":"2023","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2025.06.011_bib17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1017\/S0033291799008363","article-title":"Obstetric complications predict treatment response in first-episode schizophrenia","volume":"29","author":"Alvir","year":"1999","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2025.06.011_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2025.06.011_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and safety of clozapine in psychotic disorders-A systematic quantitative meta-review","volume":"11","author":"Wagner","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41386-019-0577-3","article-title":"Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: A meta-analysis","volume":"45","author":"Mizuno","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.06.011_bib23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00406-023-01654-2","article-title":"A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia","volume":"274","author":"Dong","year":"2024","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2025.06.011_bib24","first-page":"39","article-title":"Clozapine","volume":"1","author":"Schmutz","year":"1982","journal-title":"Chron Drug Discov"},{"key":"10.1016\/j.biopsych.2025.06.011_bib25","author":"Roth"},{"key":"10.1016\/j.biopsych.2025.06.011_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0893-133X(98)00048-7","article-title":"Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells","volume":"20","author":"Olianas","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.06.011_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0773.1999.tb01482.x","article-title":"Clozapine: Dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta Stone of antipsychotic drugs","volume":"84","author":"Ahlenius","year":"1999","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/cn400189s","article-title":"Clozapine, a fast-off-D2 antipsychotic","volume":"5","author":"Seeman","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.biopsych.2025.06.011_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-004-2017-1","article-title":"The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: Is M1 agonism a pre-requisite for mimicking clozapine\u2019s actions?","volume":"178","author":"Davies","year":"2005","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2025.06.011_bib30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S2215-0366(24)00100-7","article-title":"Psychosis as a disorder of muscarinic signalling: Psychopathology and pharmacology","volume":"11","author":"McCutcheon","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/WNR.0b013e328349739b","article-title":"Evidence that clozapine directly interacts on the GABAB receptor","volume":"22","author":"Wu","year":"2011","journal-title":"NeuroReport"},{"key":"10.1016\/j.biopsych.2025.06.011_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.schres.2023.09.027","article-title":"A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia","volume":"268","author":"Cheuk","year":"2024","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2025.06.011_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4693","article-title":"Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: A systematic review and meta-analysis","volume":"3","author":"Beck","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2025.06.011_bib34","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2025.06.011_bib35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamapsychiatry.2024.3846","article-title":"Linking genome-wide association studies to pharmacological treatments for psychiatric disorders","volume":"82","author":"Arnatkeviciute","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000054937","article-title":"Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine","volume":"44","author":"Tortorella","year":"2001","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.biopsych.2025.06.011_bib37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/schbul\/sbaa128","article-title":"Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: A multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA)","volume":"47","author":"Egerton","year":"2021","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2025.06.011_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neuint.2007.06.019","article-title":"Phencyclidine animal models of schizophrenia: Approaches from abnormality of glutamatergic neurotransmission and neurodevelopment","volume":"51","author":"Mouri","year":"2007","journal-title":"Neurochem Int"},{"key":"10.1016\/j.biopsych.2025.06.011_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0074-7742(06)78003-5","article-title":"Glutamate and schizophrenia: Phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions","volume":"78","author":"Javitt","year":"2007","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib40","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","article-title":"N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity","volume":"100","author":"Sur","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2025.06.011_bib41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/biom9060234","article-title":"Clozapine normalizes a glutamatergic transmission abnormality induced by an impaired NMDA receptor in the thalamocortical pathway via the activation of a group III metabotropic glutamate receptor","volume":"9","author":"Fukuyama","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopsych.2025.06.011_bib42","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/schbul\/sbaa156","article-title":"Changes in brain glutamate on switching to clozapine in treatment-resistant schizophrenia","volume":"47","author":"McQueen","year":"2021","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2025.06.011_bib43","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1177\/0269881112450780","article-title":"A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia","volume":"26","author":"Rizig","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib44","first-page":"185","article-title":"Pharmacogenetic analysis of functional glutamate system gene variants and clinical response to clozapine","volume":"2","author":"Taylor","year":"2017","journal-title":"Mol Neuropsychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.830757","article-title":"Clozapine reverses dysfunction of glutamatergic neurons derived from clozapine-responsive schizophrenia patients","volume":"16","author":"Hribkova","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.biopsych.2025.06.011_bib46","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.biopsych.2017.12.006","article-title":"Sodium Benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial","volume":"84","author":"Lin","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/ijnp\/pyad035","article-title":"Phase 2 results indicate evenamide, a selective modulator of glutamate release, is associated with clinically important long-term efficacy when added to an antipsychotic in patients with treatment-resistant schizophrenia","volume":"26","author":"Anand","year":"2023","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib48","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1017\/S0033291716002476","article-title":"Adjunctive memantine in clozapine-treated refractory schizophrenia: An open-label 1-year extension study","volume":"47","author":"Veerman","year":"2017","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2025.06.011_bib49","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamapsychiatry.2017.2663","article-title":"Heterogeneity and homogeneity of regional brain structure in schizophrenia: A meta-analysis","volume":"74","author":"Brugger","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: State of the art and new directions","volume":"27","author":"Howes","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib51","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/jamapsychiatry.2021.0380","article-title":"Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: A mega-analysis of individual participant-level data","volume":"78","author":"Merritt","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib52","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fpsyt.2017.00066","article-title":"Effects of antipsychotic administration on brain glutamate in schizophrenia: A systematic review of longitudinal 1H-MRS studies","volume":"8","author":"Egerton","year":"2017","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.967941","article-title":"The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: A 1H-MRS study in first-episode psychosis patients","volume":"13","author":"Zahid","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110473","article-title":"Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients","volume":"113","author":"Reyes-Madrigal","year":"2022","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib55","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41386-022-01508-w","article-title":"Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: Data from the STRATA collaboration","volume":"48","author":"Egerton","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.06.011_bib56","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1017\/S0033291700047942","article-title":"Adverse effects of anticholinergic medication on positive schizophrenic symptoms","volume":"13","author":"Johnstone","year":"1983","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2025.06.011_bib57","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.mp.4001924","article-title":"Towards a muscarinic hypothesis of schizophrenia","volume":"12","author":"Raedler","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000293586","article-title":"Cholinergic aspects of schizophrenia","volume":"174","author":"Tandon","year":"1999","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.biopsych.2025.06.011_bib59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1017\/S1461145706006584","article-title":"Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine","volume":"10","author":"Raedler","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib60","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","article-title":"Safety and tolerability of KarXT (xanomeline\u2013trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia (Heidelb)"},{"key":"10.1016\/j.biopsych.2025.06.011_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2024.104320","article-title":"Finally, a non-dopaminergic antipsychotic (xanomeline-Trospium) for treatment of schizophrenia: Significance and learnings","volume":"102","author":"Tandon","year":"2024","journal-title":"Asian J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib63","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","article-title":"Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: A two-part, randomised, double-blind, placebo-controlled, phase 1b trial","volume":"400","author":"Krystal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2025.06.011_bib64","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0922-4106(94)90047-7","article-title":"Clozapine is a potent and selective muscarinic M4 receptor agonist","volume":"269","author":"Zorn","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib65","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ajp.2015.14050673","article-title":"Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine","volume":"172","author":"Rajji","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib67","author":"Bristol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib68","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1093\/brain\/awae186","article-title":"Cholinergic deficiency in Parkinson\u2019s disease patients with visual hallucinations","volume":"147","author":"d\u2019Angremont","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2025.06.011_bib69","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/mdc3.13582","article-title":"Clozapine is severely underused in Parkinson\u2019s disease patients","volume":"9","author":"Friedman","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.biopsych.2025.06.011_bib70","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1176\/appi.ajp.161.9.1620","article-title":"Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: Differentiation from other atypical antipsychotics","volume":"161","author":"Tauscher","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.schres.2022.09.012","article-title":"Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension","volume":"248","author":"Kane","year":"2022","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2025.06.011_bib72","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1021\/acs.jmedchem.7b00151","article-title":"Return of D4 dopamine receptor antagonists in drug discovery","volume":"60","author":"Lindsley","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopsych.2025.06.011_bib73","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib74","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2025.06.011_bib75","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.2174\/1570159X19666210125152815","article-title":"Recent discussions on dopamine supersensitivity psychosis: Eight points to consider when diagnosing treatment-resistant schizophrenia","volume":"19","author":"Kanahara","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib76","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/0024-3205(83)90759-2","article-title":"The effect of chronic neuroleptic administration on cerebral dopamine receptor function","volume":"32","author":"Rupniak","year":"1983","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2025.06.011_bib77","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","article-title":"\u201cBreakthrough\u201d dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time","volume":"27","author":"Samaha","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2025.06.011_bib78","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004850-199705000-00001","article-title":"A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia","volume":"12","author":"Hong","year":"1997","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib79","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/0269881119862535","article-title":"Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review","volume":"33","author":"Pardis","year":"2019","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib80","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1192\/bjp.bp.116.182683","article-title":"Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?","volume":"209","author":"Murray","year":"2016","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib81","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/YIC.0000000000000160","article-title":"Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia","volume":"32","author":"Nakata","year":"2017","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib82","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S2215-0366(20)30264-9","article-title":"Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: An individual participant data meta-analysis","volume":"7","author":"Rubio","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib83","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pnpbp.2013.10.003","article-title":"Is schizophrenia a dopamine supersensitivity psychotic reaction?","volume":"48","author":"Seeman","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib84","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/npp.2012.91","article-title":"Chronic \u03949-tetrahydrocannabinol exposure induces a sensitization of dopamine D2\/3 receptors in the mesoaccumbens and nigrostriatal systems","volume":"37","author":"Ginovart","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.06.011_bib85","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/schbul\/sbad139","article-title":"Does slow and steady win the race? Rates of antipsychotic discontinuation, antipsychotic dose, and risk of psychotic relapse","volume":"50","author":"McCutcheon","year":"2024","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2025.06.011_bib86","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.npp.1300157","article-title":"Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine","volume":"28","author":"Lieberman","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.06.011_bib87","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2215-0366(24)00366-3","article-title":"Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: A population-based cohort study","volume":"12","author":"Taipale","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib88","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biopsych.2018.06.016","article-title":"Associations between non-neurological autoimmune disorders and psychosis: A meta-analysis","volume":"85","author":"Cullen","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib90","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/schbul\/sbx035","article-title":"Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder, and depression","volume":"44","author":"Wang","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2025.06.011_bib91","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.schres.2017.08.063","article-title":"Brain TSPO imaging and gray matter volume in schizophrenia patients and in people at ultra high risk of psychosis: An [11C]PBR28 study","volume":"195","author":"Selvaraj","year":"2018","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2025.06.011_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2020.12.020","article-title":"Peripheral immune markers and antipsychotic non-response in psychosis","volume":"230","author":"Enache","year":"2021","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2025.06.011_bib93","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41386-024-01932-0","article-title":"Is treatment-resistant schizophrenia a neuroimmune condition? Meta-analytic evidence from magnetic resonance spectroscopy","volume":"50","author":"Smucny","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.06.011_bib94","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/cells9030577","article-title":"Clozapine prevents poly (I:C) induced inflammation by modulating NLRP3 pathway in microglial cells","volume":"9","author":"Giridharan","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopsych.2025.06.011_bib95","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00004714-199610000-00011","article-title":"Effects of clozapine on plasma cytokine and soluble cytokine receptor levels","volume":"16","author":"Pollm\u00e4cher","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib96","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","article-title":"Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever","volume":"34","author":"Kluge","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2025.06.011_bib97","first-page":"1251","article-title":"Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia","volume":"24","author":"L\u00fc","year":"2004","journal-title":"Di Yi Jun Yi Da Xue Xue Bao"},{"key":"10.1016\/j.biopsych.2025.06.011_bib98","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JCP.0000000000001329","article-title":"Clozapine response in schizophrenia and hematological changes","volume":"41","author":"Blackman","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1192\/bjp.2018.152","article-title":"Clozapine is associated with secondary antibody deficiency","volume":"214","author":"Ponsford","year":"2019","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib100","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/jclinpath-2019-206235","article-title":"Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID)","volume":"73","author":"Ponsford","year":"2020","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib101","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbi.2023.10.001","article-title":"Changes in immunoglobulin levels during clozapine treatment in schizophrenia","volume":"115","author":"Griffiths","year":"2024","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.biopsych.2025.06.011_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1356975","article-title":"Neuroinflammation and schizophrenia \u2013 Is there a link?","volume":"15","author":"Chaves","year":"2024","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib103","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamapsychiatry.2023.5371","article-title":"Associations of the gut microbiome with treatment resistance in schizophrenia","volume":"81","author":"Vasileva","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib104","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/08039489409081367","article-title":"Clozapine decreases the level of anxiety and aggressive behaviour in patients with therapy-refractory schizophrenia","volume":"48","author":"Rim\u00f3n","year":"1994","journal-title":"Nord J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0091-3057(90)90125-2","article-title":"Anxiolytic potential of sulpiride, clozapine and derivatives in the open-field test","volume":"36","author":"Bruhwyler","year":"1990","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2025.06.011_bib106","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0091-3057(93)90237-N","article-title":"Effects of four antipsychotics on punished responding in rats","volume":"45","author":"Wiley","year":"1993","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2025.06.011_bib107","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0091-3057(93)90079-9","article-title":"Effects of atypical antipsychotic agents on social behavior in rodents","volume":"45","author":"Corbett","year":"1993","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2025.06.011_bib108","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.pbb.2008.04.014","article-title":"Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: Contrast with haloperidol and chlordiazepoxide","volume":"90","author":"Mead","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2025.06.011_bib109","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/DDDT.S89485","article-title":"Quetiapine monotherapy in acute treatment of generalized anxiety disorder: A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Maneeton","year":"2016","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.biopsych.2025.06.011_bib110","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2215-0366(17)30134-7","article-title":"Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: A nationwide cohort study","volume":"4","author":"Tiihonen","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.euroneuro.2022.12.011","article-title":"Prevention of suicide by clozapine in mental disorders: Systematic review","volume":"69","author":"Masdrakis","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib112","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpsychires.2020.02.026","article-title":"Clozapine in bipolar disorder: A systematic review and meta-analysis","volume":"125","author":"Delgado","year":"2020","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2025.06.011_bib113","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: Systematic overview and quality appraisal of the meta-analytic evidence","volume":"74","author":"Correll","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib114","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1017\/S0033291701003312","article-title":"A cognitive model of the positive symptoms of psychosis","volume":"31","author":"Garety","year":"2001","journal-title":"Psychol Med"},{"key":"10.1016\/j.biopsych.2025.06.011_bib115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/02698811221142575","article-title":"Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis","volume":"37","author":"Rafizadeh","year":"2023","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib116","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.schres.2023.11.008","article-title":"A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder","volume":"268","author":"Faden","year":"2024","journal-title":"Schizophr Res"},{"issue":"suppl","key":"10.1016\/j.biopsych.2025.06.011_bib117","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/BF00442554","article-title":"Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia","volume":"99","author":"Meltzer","year":"1989","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2025.06.011_bib118","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231168788","article-title":"High-dose olanzapine in treatment-resistant schizophrenia: A systematic review","volume":"13","author":"Gannon","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib119","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/02698811251319458","article-title":"The mechanism of action of clozapine","volume":"39","author":"Morrison","year":"2025","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.06.011_bib120","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23nr15240","article-title":"Rationale for adjunctive treatment targeting multiple mechanisms in schizophrenia","volume":"85","author":"Kinon","year":"2024","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib121","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.biopsych.2023.04.004","article-title":"Data-driven taxonomy for antipsychotic medication: A new classification system","volume":"94","author":"McCutcheon","year":"2023","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.06.011_bib122","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/acps.12700","article-title":"The impact of clozapine on hospital use: A systematic review and meta-analysis","volume":"135","author":"Land","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.biopsych.2025.06.011_bib123","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archpsyc.56.6.565","article-title":"Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia","volume":"56","author":"Rosenheck","year":"1999","journal-title":"Arch Gen Psychiatry"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322325012703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322325012703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:30:25Z","timestamp":1773221425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322325012703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":122,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0006322325012703"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2025.06.011","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why Is Clozapine Uniquely Effective in Treatment-Resistant Schizophrenia? A Review and Proposal","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2025.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}